NeuroKit® Installed for First U.S. Clinical Studies
9 December 2025
CHDR, Lotus Clinical Research, and Evolution Research Group have taken a major step in CNS research by installing NeuroKit® at Clinical Pharmacology of Miami (CPMI), paving the way for the first U.S. trials using this innovative cognitive biomarker platform.
A significant milestone for CNS drug development: NeuroKit®, CHDR’s portable platform for standardized CNS testing, has been installed at Clinical Pharmacology of Miami (CPMI). This marks the beginning of a series of U.S. clinical studies designed to accelerate CNS research through accurate, repeatable cognitive biomarkers.
By combining CHDR’s innovation with the clinical expertise of Lotus Clinical Research and Evolution Research Group (ERG), this collaboration ensures high-quality, reproducible data for sponsors across the United States. NeuroKit® builds on CHDR’s validated NeuroCart® technology, offering a streamlined solution for pharmacodynamic testing in early-phase trials.
This installation represents a shared commitment to advancing CNS drug development and improving access to robust biomarker data. More studies are planned for 2025 and beyond.
Want to learn more about NeuroKit®? Explore more here.